Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20975309 | 1.00 | KDM4E (0.43) | KDM4EL3MBTL1HTTPOLBNPC1 | |
| SCHEMBL30706513 | 0.93 | FKBP1A (0.43) | KDM4EHTTPOLBNPC1CYP3A4 | |
| SCHEMBL21000134 | 0.93 | FKBP1A (0.43) | KDM4EHTTPOLBNPC1CYP3A4 | |
| SCHEMBL29740475 | 0.89 | TRPV1 (0.41) | KDM4EHTTPOLBNPC1CYP3A4 | |
| SCHEMBL18575373 | 0.89 | TRPV1 (0.41) | KDM4EHTTPOLBNPC1CYP3A4 | |
| SCHEMBL23627805 | 0.89 | TRPV1 (0.41) | KDM4EHTTPOLBNPC1CYP3A4 | |
| SCHEMBL22272706 | 0.87 | KDM4E (0.43) | KDM4EHTTPOLBNPC1CYP3A4 | |
| SCHEMBL7709759 | 0.86 | KDM4E (0.44) | KDM4EL3MBTL1HTTPOLBALDH1A1 | |
| SCHEMBL3931727 | 0.86 | KDM4E (0.41) | KDM4EHTTPOLBNPC1CYP3A4 | |
| SCHEMBL14072136 | 0.86 | KDM4E (0.41) | KDM4EHTTPOLBNPC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-01-04 | — | — | US | disclosed |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | KDM4E 3451/4885L3MBTL1 1770/4885HTT 3874/4885 |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | KDM4E 3476/4885L3MBTL1 1709/4885HTT 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.